



**Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

December 7, 2010 6:30 – 9:00 p.m.

- 1. Executive Session** **6:30 - 7:00**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

- 2. Introductions and Approval of DUR Board Minutes** **7:00 - 7:05**
(Public Comment Prior to Board Action)

- 3. DVHA Pharmacy Administration Updates** **7:05 - 7:10**

- 4. Medical Director Update** **7:10 - 7:15**
 - Clinical Programs Update
 - Prescriber Comments

- 5. Follow-up Items from Previous Meeting** **7:15 - 7:35**
 - Long Acting Narcotics Clinical Criteria
 - Suboxone[®]/Suboxone Film[®]/Subutex[®] (buprenorphine)
 - Urinary Antispasmodics

- 6. RetroDUR/Prior Authorization Quality Assurance Analysis** **7:35 - 7:50**
 - Azithromycin
 - RetroDUR/Educational Activities Currently in Process
 - Asthma
 - Seroquel[®] – Low dose for anxiety or hypnotic

- 7. Clinical Update: Drug Reviews** **7:50 – 8:25**
(Public comment prior to Board action)
 - Abbreviated Drug Review**
 - Colcrys[®](colchicine) Tablet

 - Full New Drug Reviews**
 - Livalo[®] (pitavastatin) Tablet
 - Pradaxa[®] (dabigatran etexilate) Capsule
 - Prolia[®] (denosumab) Subcutaneous Injection
 - Xifaxan[®] (rifaximin) 550 mg Tablet
 - Zymaxid[®] (gatifloxacin) Ophthalmic Solution

- 8. Therapeutic Drug Classes – Periodic Review** **8:25 – 8:35**
(Public comment prior to Board action)
Class review documents available on DVHA web site 12/07/2010 @ 12 Noon
- Leukotriene Modifiers
- 9. New Managed Therapeutic Drug Classes** **8:35 – 8:35**
(Public comment prior to Board action)
- No new categories this meeting
- 10. Brand to Generic Changes** **8:35 – 8:40**
- Informational Only
- 11. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products** **8:40 – 8:55**
(Public comment prior to Board action)
- BPH: Alpha Blockers
 - BPH: Androgen Hormone Inhibitors
 - Ossification Enhancers
 - Pancreatic Enzymes
 - Prenatal Vitamins
- 12. General Announcements** **8:55 – 9:00**
Selected FDA Safety Alerts
- Propoxyphene: Withdrawal - Risk of Cardiac Toxicity
- 13. Adjourn** **9:00**